Side-by-side comparison of AI visibility scores, market position, and capabilities
Santa Rosa electronic test and measurement (NYSE: KEYS) at ~$5B revenue; record Q4 with 14% order growth driven by AI datacenter testing and 6G research, Spirent $1.5B acquisition (2024) competing with Rohde & Schwarz.
Keysight Technologies, Inc. is a Santa Rosa, California-based electronic design, test, and measurement solutions company — publicly traded on the New York Stock Exchange (NYSE: KEYS) as an S&P 500 Information Technology component — providing hardware instruments, software platforms, and services for designing, testing, and validating electronic systems across 5G/6G wireless, AI data center infrastructure, aerospace and defense, automotive, and quantum computing through approximately 15,500 employees with approximately $5 billion in annual revenue. Keysight's heritage traces to Hewlett-Packard's test and measurement division (founded 1939), which became Agilent Technologies in 1999 and spun off Keysight as an independent company in 2014. In its most recent fiscal quarter, Keysight reported 14% order growth, 10% revenue growth to $1.42 billion, and 16% higher adjusted EPS — its best quarterly performance in two years — driven by demand for AI data center testing, early 6G wireless infrastructure research, and defense electronics modernization, alongside contributions from three major acquisitions completed in October 2024. The company's key acquisitions include Spirent Communications ($1.5 billion, 2024, network test and cybersecurity validation), ESI Group ($1 billion, 2023, electromagnetic simulation), and Ixia ($1.6 billion, 2017, network testing). Keysight's PathWave software platform integrates design simulation, test automation, and analytics workflows into a unified environment that semiconductor and wireless chipset teams use to accelerate development cycles from simulation to hardware validation.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.